• Teva proposes to buy Mylan for $40.1 billion biospectrumasia
    November 16, 2018
    He added that Mylan's business is a natural fit with Teva and is highly complementary to it. Merging the two companies would not only deliver the greatest value
PharmaSources Customer Service